Cameron Gray
Founder at Itolerance, Inc.
Profile
Cameron Gray is the founder of Alcedo Capital, Inc. (2019).
He is currently a Director at Viewpoint Molecular Targeting, Inc. Dr. Gray's former positions include CEO, CFO, Secretary, Treasurer & Director at Endeavor IP, Inc. (2013-2014), Managing Director at Public Ventures LLC (2013-2019), Independent Director at Cue Biopharma, Inc. (2016-2022), Director at Provention Bio, Inc. (2017-2019), and Senior Vice President at ICAP Patent Brokerage LLC (2009-2012).
Dr. Gray received a doctorate from the University of Virginia in 1997, an undergraduate degree from Princeton University in 1992, and a graduate degree from George Washington University Law School in 2006.
Dr. Gray is also the founder of Itolerance, Inc...
Cameron Gray active positions
| Companies | Position | Start |
|---|---|---|
Viewpoint Molecular Targeting, Inc.
 Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA. | Director/Board Member | - |
Itolerance, Inc.
 Itolerance, Inc. BiotechnologyHealth Technology Itolerance, Inc. is an American biotechnology company that specializes in developing regenerative medicines. The private company was founded by Cameron Gray and is currently led by CEO Anthony J. Japour. | Founder | - |
Former positions of Cameron Gray
| Companies | Position | End |
|---|---|---|
| CUE BIOPHARMA, INC. | Chief Executive Officer | 31/07/2016 |
Public Ventures LLC
 Public Ventures LLC Investment Banks/BrokersFinance Public Ventures LLC is a registered broker-dealer headquartered in Dallas, Texas. The firm was founded by Christopher Marlett and Anthony DiGiandomenico in 1997. They are a wholly-owned subsidiary of MDB Capital Holdings LLC. Public Ventures offers Go-to-Market Strategy, Market Assessments, Revenue Generation and Product Strategy for technology companies that targets the Public Sector. | Corporate Officer/Principal | 31/10/2019 |
| PROVENTION BIO, INC. | Director/Board Member | 28/05/2019 |
| ENDEAVOR IP INC | Chief Executive Officer | 02/01/2014 |
ICAP Patent Brokerage LLC
 ICAP Patent Brokerage LLC Real Estate DevelopmentFinance ICAP Patent Brokerage LLC provides intellectual property brokerage, live patent auction, and sealed-bid patent auction services. It operates a live auctioning platform for the buyers and sellers of patents and other intellectual property assets. The company is headquartered in New York, NY. | Corporate Officer/Principal | 31/12/2011 |
Training of Cameron Gray
| George Washington University Law School | Graduate Degree |
| University of Virginia | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CUE BIOPHARMA, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Endeavor IP, Inc.
 Endeavor IP, Inc. Miscellaneous Commercial ServicesCommercial Services Endeavor IP, Inc. engages in the acquisition, development, and commercialization of intellectual property assets. The company was founded on December 8, 2009 and is headquartered in Vienna, VA. | Commercial Services |
ICAP Patent Brokerage LLC
ICAP Patent Brokerage LLC Real Estate DevelopmentFinance ICAP Patent Brokerage LLC provides intellectual property brokerage, live patent auction, and sealed-bid patent auction services. It operates a live auctioning platform for the buyers and sellers of patents and other intellectual property assets. The company is headquartered in New York, NY. | Finance |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
Public Ventures LLC
Public Ventures LLC Investment Banks/BrokersFinance Public Ventures LLC is a registered broker-dealer headquartered in Dallas, Texas. The firm was founded by Christopher Marlett and Anthony DiGiandomenico in 1997. They are a wholly-owned subsidiary of MDB Capital Holdings LLC. Public Ventures offers Go-to-Market Strategy, Market Assessments, Revenue Generation and Product Strategy for technology companies that targets the Public Sector. | Finance |
Viewpoint Molecular Targeting, Inc.
Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA. | Commercial Services |
Itolerance, Inc.
Itolerance, Inc. BiotechnologyHealth Technology Itolerance, Inc. is an American biotechnology company that specializes in developing regenerative medicines. The private company was founded by Cameron Gray and is currently led by CEO Anthony J. Japour. | Health Technology |
| Alcedo Capital, Inc. |
- Stock Market
- Insiders
- Cameron Gray
